Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service debridement & negative-pressure wound therapy cases in Oklahoma: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 177 | 62,607 | 24% |
| 2020 | 181 | 59,384 | 28% |
| 2021 |
Surgical and selective debridement; NPWT, durable and disposable. Professional codes (what the surgeon bills): CPT 11042, 11043, 11044, 97597, 97605, 97606, 97607, 97608; the hospital bills MS-DRG 463, 464, 465.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 29% of the cases CMS names in Oklahoma; 67 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Skin substitutes & wound grafts | 48 | 11,719+21%/yr | +21%/yr | 16.61.5× | 72% | 19,200 in 2030+8.6%/yr |
| Bone graft & orthobiologics |
Debridement & negative-pressure wound therapy in every state, and its device makers · Every procedure market in Oklahoma · Every state · Compare with Florida
| 2024 |
| 53,727 |
| 44% |
| 2025 est. | ≈ 57,800 | – |
| 2026 est. | ≈ 58,000 | – |
| 161 |
| 60,835 |
| 34% |
| 2022 | 166 | 55,358 | 38% |
| 2023 | 164 | 50,834 | 42% |
| 2024 | 201 | 53,727 | 44% |
| 2025 from claims | – | 57,764 53,011–61,114 | 46% |
| 2026 forecast | – | 57,978 51,011–66,903 | 46% |
| 2027 forecast | – | 58,296 49,836–69,471 | 47% |
| 2028 forecast | – | 58,604 48,899–71,759 | 48% |
| 2029 forecast | – | 58,901 48,108–73,867 | 49% |
| 2030 forecast | – | 59,187 47,417–75,848 | 49% |
In 2025, 6% inpatient hospital, 54% hospital outpatient, 40% office. The share outside the hospital has moved +7 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~58,000 | ~3,400 | ~31,200 | ~23,400 |
| 2027 · ~58,300 | ~3,400 | ~31,300 | ~23,600 |
| 2028 · ~58,600 | ~3,400 | ~31,500 | ~23,700 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| 283,370+3.6%/yr |
| +3.6%/yr |
| 125.0 |
| 51% |
| 394,700 in 2030+5.7%/yr |
| North Carolina | 411 | 84,720−6.3%/yr | −6.3%/yr | 81.1 | 34% | 87,500 in 2030+0.5%/yr |
| Maryland | 326 | 74,510−0.7%/yr | −0.7%/yr | 82.4 | 45% | 93,400 in 2030+3.8%/yr |
| Tennessee | 333 | 72,572+0.2%/yr | +0.2%/yr | 98.4 | 42% | 88,600 in 2030+3.4%/yr |
| Virginia | 344 | 68,692−0.3%/yr | −0.3%/yr | 63.2 | 42% | 87,800 in 2030+4.2%/yr |
| Georgia | 343 | 64,759−1.7%/yr | −1.7%/yr | 71.2 | 53% | 79,900 in 2030+3.6%/yr |
| Louisiana | 246 | 53,907−1.2%/yr | −1.2%/yr | 125.3 | 42% | 63,600 in 2030+2.8%/yr |
| Mississippi | 171 | 53,180+8.6%/yr | +8.6%/yr | 136.3 | 38% | 92,200 in 2030+9.6%/yr |
| Kentucky | 219 | 49,665−0.1%/yr | −0.1%/yr | 103.0 | 29% | 64,000 in 2030+4.3%/yr |
| South Carolina | 212 | 49,045+6%/yr | +6%/yr | 68.6 | 32% | 64,600 in 2030+4.7%/yr |
| Alabama | 164 | 36,065−4.8%/yr | −4.8%/yr | 77.6 | 30% | 39,500 in 2030+1.5%/yr |
| Arkansas | 132 | 29,280−1.7%/yr | −1.7%/yr | 74.3 | 32% | 33,700 in 2030+2.4%/yr |
| West Virginia | 70 | 14,070−5.5%/yr | −5.5%/yr | 64.1 | 37% | 13,100 in 2030−1.2%/yr |
| Delaware | 57 | 12,034+3.1%/yr | +3.1%/yr | 68.1 | 37% | 18,400 in 2030+7.3%/yr |
| District of Columbia | 34 | 5,774−6.9%/yr | −6.9%/yr | 88.9 | 51% | 6,110 in 2030+1%/yr |
| 13 |
| 397−18%/yr |
| −18%/yr |
| 0.81.2× |
| 1% |
| 430 in 2030+1.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Angiodynamics leads with 51% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 24 companies reported engagement with Oklahoma’s surgeons worth $107K in consulting, speaking, meals and travel tied to these products, about $532 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 10 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.